| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | MGTA | Common Stock | 1.27M | Sep 11, 2023 | See footnote | F1, F2, F3 |
| Id | Content |
|---|---|
| F1 | Effective as of September 11, 2023 (the "Effective Time"), a wholly-owned subsidiary of Magenta Therapeutics, Inc. ("Magenta"), merged (the "Merger") with and into Dianthus Therapeutics, Inc. ("Dianthus") resulting in, among other things, Dianthus becoming a wholly owned subsidiary of Magenta. At the Effective Time, Magenta effected a name change to "Dianthus Therapeutics, Inc." (hereinafter, the "Issuer"). |
| F2 | Represents the number of shares of common stock of the Issuer received by the Reporting Person in the Merger in exchange for the shares of Dianthus held by the Reporting Person prior to the Merger. Each share of Dianthus common stock held at the Effective Time was exchanged for 0.2181 shares of the Issuer's common stock, which gives effect to the reverse stock split of common stock effected by the Issuer and the Merger exchange ratio. |
| F3 | The securities reported are held of record by Tellus BioVentures, LLC ("Tellus"). The Reporting Person is the sole managing member of Tellus and may be deemed to have sole voting and dispositive power over the shares held by Tellus. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. |
Exhibit 24 - Power of Attorney